Olanzapine is widely used in treating multiple domains of schizophrenia symptoms but induces serious metabolic side-effects. Recent evidence has showed that co-treatment of betahistine (a histaminergic H 1 receptor agonist and H 3 receptor antagonist) is effective for preventing olanzapine-induced weight gain/obesity, however it is not clear whether this co-treatment affects on the primary therapeutic receptor binding sites of olanzapine such as 
Introduction
Second generation antipsychotic drugs (SGAs) such as olanzapine have been used not only to ameliorate schizophrenia symptoms but also used widely for other mental disorders such as bipolar disorder, depression, and Tourette's syndrome (Lambert, 2011) . However, these drugs could induce serious metabolic side-effects including body weight gain and obesity (Allison et al., 1999; Correll et al., 2011; Stahl et al., 2009) . In contrast to first generation antipsychotic drugs (FGAs) (e.g. chlorpromazine and haloperidol) as a potent dopamine D 2 receptor (D 2 R) antagonist, SGAs (such as olanzapine) have high affinities not only to D 2 R but also to a wide range of non-dopaminergic G-proteincoupled receptors, including histaminergic H 1 (H 1 R), serotonergic 5-HT 2A (5-HT 2A R) and 5-HT 2C (5-HT 2C R), muscarinic M 1 (M 1 R) and adrenergic α 1-2 (α 1-2 R) receptors (Nasrallah, 2008; Richelson and Souder, 2000) . The binding affinities of olanzapine to these neurotransmitter receptors are ranked in the following order: H 1 R N 5-HT 2 R N D 2 R N αR and M 1 R (Uchida et al., 2007) . Since a number of studies have shown that H 1 R plays a key role in olanzapine induced weight gain/obesity (Deng et al., 2010; Han et al., 2008a; He et al., 2013; Kim et al., 2007) , H 1 R could be a therapeutic target for controlling olanzapine-induced weight gain side-effects. Recently we found in a rat model that olanzapine-induced weight gain can be partially reduced (−45%) by co-treatment with betahistine (an H 1 R agonist and H 3 R antagonist) (Deng et al., 2012) . This finding was confirmed by a recent clinical report that schizophrenia patients with a combination treatment of olanzapine, betahistine and reboxetine (a selective norepinephrine reuptake inhibitor) had significantly less weight gain than those on olanzapine only (Poyurovsky et al., 2013) . In addition, a small clinical
